TuHURA Biosciences, Inc. (HURA)

NASDAQ: HURA · Real-Time Price · USD

3.250

+0.340 (11.68%)

Aug 22, 2025, 4:00 PM - Market closed

TuHURA Biosciences Employees

TuHURA Biosciences had 19 employees as of December 31, 2024. The number of employees increased by 18 or 1,800.00% compared to the previous year.

Employees

19

Change (1Y)

18

Growth (1Y)

1,800.00%

Revenue / Employee

n/a

Profits / Employee

-$1,512,346

Market Cap

162.65M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	19	18	1,800.00%
Dec 31, 2023	1	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

HURA News

4 days ago - TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference - PRNewsWire
10 days ago - TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
6 weeks ago - Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development - GlobeNewsWire
7 weeks ago - TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - PRNewsWire
7 weeks ago - TuHURA Biosciences Completes Acquisition of Kineta - PRNewsWire
2 months ago - TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma - PRNewsWire
2 months ago - TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - PRNewsWire
2 months ago - FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma - PRNewsWire